丹纳赫
DHR
229.04
-2.46
-1.06%
丹纳赫
US · DHR
#143 按市值排名
上市于 1970
229.04
-2.46
-1.06%
实时 - 追踪5344个代码 - 心跳于508秒前
· 2026-10-16 20:01
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了6家。
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 83.88% -0.07pp
- 机构数量
- 2,491 -6
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund69.13%
Individual/Insider10.86%
Hedge Fund4.25%
Public Company3.77%
Private Company1.90%
Government Pension Fund1.79%
Sovereign Wealth Fund1.42%
Family Office/Trust0.68%
Insurance Company0.28%
Other5.91%
主要股东 截至 2026-06-30
BlackRock
7.84% · 55.08M 股
Vanguard Capital Management, LLC
6.39% · 44.92M 股
Steven Rales
6.01% · 42.24M 股
Mitchell Rales
4.80% · 33.77M 股
State Street Global Advisors
4.05% · 28.46M 股
Other
70.91%
Capital Research
3.82% · 26.87M 股
FMR
3.78% · 26.54M 股
T. Rowe Price Group, Inc.
2.61% · 18.37M 股
Wellington Management Group
2.32% · 16.32M 股
Geode Capital Management, LLC
2.03% · 14.28M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 38次买入 · 6次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Steven Rales | Chairperson | 6.01% |
| Mitchell Rales | Co-Founder | 4.80% |
| Alan Spoon | Independent Director | 0.01% |
| John Schwieters | Independent Director | 0.01% |
| Rainer Blair | Chief Executive Officer | 0.01% |
| Matthew McGrew | Chief Financial Officer | 0.00% |
| Linda Filler | Lead Independent Director | 0.00% |
| Elias Zerhouni | Independent Director | 0.00% |
| Brian Ellis | Senior VP, General Counsel & Chief Compliance Officer | 0.00% |
| Daniel Raskas | Officer | 0.00% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-30 | Shashanka Muppaneni | Chief Strategy Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-09-30 | Heathre Moler | Senior VP & CHRO | Initial Statement of Beneficial | 0 | -- |
| 2026-08-20 | Rainer Blair | Chief Executive Officer | Open Market Disposition | -58,255 | $217.77–219.35 |
| 2026-08-03 | Steven Rales | Chairperson | Other Acquisition | +500,000 | -- |
| 2026-08-03 | Steven Rales | Chairperson | Other Derivative Acquisition | +1,000,000 | $194.78 |
| 2026-08-03 | Mitchell Rales | Co-Founder | Other Acquisition | +500,000 | -- |
| 2026-08-03 | Mitchell Rales | Co-Founder | Other Derivative Acquisition | +1,000,000 | $194.78 |
| 2026-08-03 | Gregory Milosevich | Executive Vice President of Life Sciences Business | Other Acquisition | +15,402 | -- |
| 2026-08-03 | Jose-Carlos Gutierrez-Ramos | Senior VP & Chief Science Officer | Other Acquisition | +13,477 | -- |
| 2026-08-03 | Matthew Gugino | Former VP of Investor Relations and FP&A | Other Derivative Acquisition | +153,563 | $194.78 |
| 2026-08-03 | Jonathan Leiken | General Counsel | Other Derivative Acquisition | +92,138 | $194.78 |
| 2026-08-03 | Christopher Riley | Executive VP of Biotechnology Group & CEO of Cytiva | Other Acquisition | +41,072 | -- |
| 2026-08-03 | Christopher Bouda | Vice President | Other Derivative Acquisition | +12,286 | $194.78 |
| 2026-08-03 | Julie Montgomery | Executive Vice President of Diagnostics | Other Derivative Acquisition | +245,701 | $194.78 |
| 2026-07-30 | Alan Spoon | Independent Director | Other Derivative Acquisition | +229 | -- |
| 2026-07-30 | Elias Zerhouni | Independent Director | Other Derivative Acquisition | +236 | -- |
| 2026-07-30 | Raymond Stevens | Independent Director | Other Derivative Acquisition | +181 | -- |
| 2026-07-30 | Linda Filler | Lead Independent Director | Other Derivative Acquisition | +18 | -- |
| 2026-07-30 | Teri List-Stoll | Independent Director | Other Derivative Acquisition | +15 | -- |
| 2026-07-30 | A. Sanders | Independent Director | Other Derivative Acquisition | +211 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:01:27 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
丹纳赫 讨论区 0 条评论